Bard® LifeStent® Vascular Stent Delivery System Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01179984
Recruitment Status : Completed
First Posted : August 11, 2010
Results First Posted : March 9, 2017
Last Update Posted : March 9, 2017
Information provided by (Responsible Party):
C. R. Bard

Brief Summary:
The purpose of this study is to evaluate the effectiveness and safety of a new delivery system for the Bard® LifeStent® Vascular Stent System.

Condition or disease Intervention/treatment Phase
Peripheral Vascular Disease Device: Bard® LifeStent® Vascular Stent System Not Applicable

Detailed Description:

Single-arm, non-randomized, prospective, multi-center study using the Bard® LifeStent® Vascular Stent Delivery System in subjects with lifestyle-limiting claudication or ischemic rest pain that are candidates for percutaneous transluminal angioplasty (PTA) and stenting with lesion(s) in the infra-inguinal segment (superficial femoral artery (SFA) and/or proximal popliteal artery). Subjects will be treated with PTA followed by implantation of the Bard® LifeStent® Vascular Stent.

Clinical follow-up for all subjects will be performed prior to hospital discharge, 30-days, and 12-, 24-, and 36-months post-index procedure.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 76 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Bard® LifeStent® Vascular Stent Delivery System Study
Study Start Date : June 2010
Actual Primary Completion Date : October 2010
Actual Study Completion Date : December 2013

Arm Intervention/treatment
Experimental: PTA and study stent
Bard® LifeStent® Vascular Stent System
Device: Bard® LifeStent® Vascular Stent System
Stent Implantation

Primary Outcome Measures :
  1. Acute Effectiveness: Percentage of Stents With Successful Delivery [ Time Frame: At implantation (Day 0) ]


    Acute effectiveness defined as the successful delivery of the stent with the post-deployment stent length being within 10% of the pre-deployment length.

  2. (Safety) Freedom From Occurrence of Death, Amputation and TVR/TLR at 30-days Post-index Procedure. [ Time Frame: 30 day follow-up ]


    Freedom from occurrence of death, amputation and TVR/TLR at 30-days post-index procedure.

Secondary Outcome Measures :
  1. Primary Target Lesion Patency [ Time Frame: 12 months post-index procedure ]
    Percentage of participants with Primary Target Lesion Patency (TLP) at 12 months post-index procedure

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   21 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. The subject or legal representative has been informed of the nature of the evaluation, agrees to its provisions, and has signed the informed consent form (ICF).
  2. Subject agrees to comply with the protocol-mandated follow-up procedures and visits.
  3. The subject is ≥ 21 years old.
  4. Female subjects of childbearing potential must have a negative urine or serum pregnancy test within seven days prior to index procedure. Female subjects who are surgically sterile or post-menopausal are exempt from having a pregnancy test.
  5. The subject has lifestyle-limiting claudication or ischemic rest pain defined as: Rutherford Category1 2-4 (moderate claudication to ischemic rest pain).
  6. The target lesion(s) has angiographic evidence of stenosis or restenosis ≥50% or occlusion (by visual estimate) and is amenable to PTA and stenting.
  7. The total treated segment(s) must be ≤ 240 mm.
  8. The target vessel reference diameter is ≥4.0 mm and ≤6.5 mm (by visual estimate) and therefore appropriate for treatment with available stent diameters of 6.0 mm and 7.0 mm.
  9. There is angiographic evidence of at least one vessel runoff to the foot (at the level of the malleolus).

Exclusion Criteria:

  1. The subject is unable or unwilling to provide informed consent or is unable or unwilling to comply with the study follow-up procedure and visits.
  2. The subject has claudication or critical limb ischemia described as Rutherford Category1 1 (mild claudication), 5 (minor tissue loss) or 6 (major tissue loss).
  3. The subject has a known contraindication (including allergic reaction) or sensitivity to antiplatelet/anticoagulant medications, nickel, titanium or tantalum.
  4. The subject has a known sensitivity to contrast media that is not amenable to pretreatment with steroids or/and antihistamines.
  5. The subject has a history of bleeding diatheses or coagulopathy.
  6. The subject has concomitant renal failure with a creatinine of >2.5 mg/dL.
  7. The subject has concomitant hepatic insufficiency, thrombophlebitis, uremia, systemic lupus erythematosus (SLE), or deep vein thrombosis (DVT) at the time of the study procedure.
  8. The subject is receiving dialysis or immunosuppressive therapy.
  9. The subject is participating in an investigational drug or another investigational device study.
  10. The subject has another medical condition, which, in the opinion of the investigator, may cause him/her to be non-compliant with the protocol, confound the data interpretation, or is associated with limited life expectancy of less than two years.
  11. The subject has extensive peripheral vascular disease, which, in the opinion of the investigator, precludes safe insertion of an introducer sheath.
  12. The target lesion(s) is located within an aneurysm or associated with an aneurysm in the vessel segment either proximal or distal to the target lesion(s).
  13. The subject has angiographic evidence of poor inflow, which would be deemed inadequate to support a vascular bypass graft.
  14. The subject is diagnosed with septicemia at the time of the study procedure.
  15. Patients with a stent previously implanted into the target vessel.
  16. Bilateral disease in the native SFA and/or proximal popliteal artery where both limbs meet the inclusion/exclusion criteria and it is planned to treat both limbs within 30 days. Note: One limb may be enrolled in the study, but only if the second limb is planned to be treated after the 30-day follow-up visit has taken place. The limb that may be enrolled has to be the limb with the more severe lesion and the reasons for treating this specific limb will need to be stated in the CRF.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01179984

Univ. Prof. Dr. Johannes Lammer
Vienna, Austria, 1090
Herzzentrum Bad Krozingen
Bad Krozingen, Baden Württemberg, Germany, 79189
Dr. Henrik Schroeder
Berlin, Germany, 13347
Dr. Hans Krankenberg
Hamburg, Germany, 22527
Dr. Rainer Schmiedel
Kaiserslautern, Germany, 67657
Prof. Dr. med. Dietrich Pfeiffer
Leipzig, Germany, 04103
Prof. Dr. Holger Reinecke
Münster, Germany, 48149
Prof. Dr. Gunnar Tepe
Rosenheim, Germany, 83022
Sponsors and Collaborators
C. R. Bard
Principal Investigator: Thomas Zeller, MD Herzzentrum Bad Krozingen, Germany

Responsible Party: C. R. Bard Identifier: NCT01179984     History of Changes
Other Study ID Numbers: BPV-09-006
First Posted: August 11, 2010    Key Record Dates
Results First Posted: March 9, 2017
Last Update Posted: March 9, 2017
Last Verified: January 2017

Additional relevant MeSH terms:
Vascular Diseases
Peripheral Vascular Diseases
Peripheral Arterial Disease
Cardiovascular Diseases
Arterial Occlusive Diseases